全文获取类型
收费全文 | 195篇 |
免费 | 14篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 25篇 |
临床医学 | 11篇 |
内科学 | 100篇 |
皮肤病学 | 1篇 |
外科学 | 1篇 |
药学 | 3篇 |
肿瘤学 | 67篇 |
出版年
2020年 | 1篇 |
2014年 | 1篇 |
2012年 | 2篇 |
2011年 | 2篇 |
2008年 | 2篇 |
2007年 | 1篇 |
2006年 | 4篇 |
2005年 | 1篇 |
2004年 | 1篇 |
2003年 | 1篇 |
2002年 | 3篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 3篇 |
1997年 | 17篇 |
1996年 | 6篇 |
1995年 | 5篇 |
1994年 | 5篇 |
1993年 | 6篇 |
1992年 | 16篇 |
1991年 | 19篇 |
1990年 | 23篇 |
1989年 | 15篇 |
1988年 | 6篇 |
1987年 | 4篇 |
1986年 | 7篇 |
1985年 | 10篇 |
1984年 | 7篇 |
1983年 | 8篇 |
1982年 | 2篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1979年 | 1篇 |
1978年 | 4篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1973年 | 1篇 |
排序方式: 共有209条查询结果,搜索用时 15 毫秒
81.
82.
83.
A Lindemann A Ganser F Herrmann J Frisch G Seipelt G Schulz D Hoelzer R Mertelsmann 《Journal of clinical oncology》1991,9(12):2120-2127
The biologic in vivo effects of recombinant human interleukin-3 (rhIL-3) were assessed in a phase I clinical study of 30 patients with advanced malignancy. On day 1 rhIL-3 was administered by a single intravenous (IV) bolus injection, followed by subcutaneous (SC) injections once daily from day 2 to 15; at least three patients were treated at each dose level (60, 125, 250, and 500 micrograms/m2). A transient decrease of eosinophil and monocyte counts was observed immediately after IV injection of rhIL-3, whereas the neutrophil count remained unaffected. Total WBC counts and neutrophil counts increased dose dependently up to threefold, whereas a 10-fold to 50-fold rise was observed in levels of circulating eosinophils and basophils. Platelet counts increased up to twofold. Patients developed moderate increases of serum levels of soluble interleukin-2 receptors, beta 2-microglobin, and immunoglobulin M (IgM), and of the acute phase reactants, C-reactive protein (CRP), fibrinogen, and haptoglobin. An increase in interleukin-6 (IL-6) serum levels was detected in patients treated by IV bolus rhIL-3. The serum half-life of IV injected rhIL-3 was 20 +/- 3 minutes; after SC administration, 210 +/- 15 minutes. Administration of rhIL-3 was generally well tolerated, with mild fever, headache, and local reactions at the injection site being the most frequent side effects. The primary course of the underlying malignant diseases was not significantly altered by administration of rhIL-3. The results indicate that rhIL-3 acts in vivo as a multilineage hematopoietic growth factor and a weak inflammatory mediator that may be used successfully to improve states of hematopoietic failure. 相似文献
84.
85.
Preliminary clinical results demonstrate the activity of recombinant human granulocyte (rHuG) and granulocyte/macrophage (rHuGM) colony stimulating factors (CSFs) in enhancing bone marrow engraftment after autologous and allogeneic bone marrow transplantation (BMT). In several analyses of prospective, controlled clinical trials of rHuG- and rHuGM-CSF, reduced morbidity and cost, as well as improved survival have been observed. There is reason to hope that more profound understanding of the in vivo biology of these and other cytokines will lead to further reduction in morbidity and mortality associated with both autologous as well as allogeneic BMT. These advances could significantly broaden the spectrum of diseases amenable to treatment by BMT. 相似文献
86.
Summary We have analyzed cultures of malignant lymphoma cells and cells from patients with acute lymphoid leukemia in methylcellulose for their ability to from colonies. Clonogenic growth was examined in the presence or absence of fetal calf serum (FCS), platelet-poor plasma (PPP), medium conditioned by phytohemagglutininstimulated leukocytes (PHA-LCM), or irradiated allogeneic bone marrow stroma cells. Cells from 25 lymphoma patients — 17 with non-Hodgkin's lymphoma (NHL), eight with Hodgkin's disease (HD) — and from 19 patients with acute lymphocytic leukemia (ALL) were investigated. We show that colony growth can be obtained in a minority of cases (in 3 NHL, 5 HD, and 2 ALL) and that the use of FCS and allogeneic irradiated stroma cells may be required for optimal colony formation.This work was supported by theDeutsche Forschungsgemeinschaft (Str 250/2-2). 相似文献
87.
88.
Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor 总被引:1,自引:0,他引:1
F Herrmann G Schulz A Lindemann W Meyenburg W Oster D Krumwieh R Mertelsmann 《Journal of clinical oncology》1989,7(2):159-167
The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 patients with advanced malignancy in a phase Ib trial. Patients were treated at four different dose levels (120 to 1,000 micrograms/m2/d) by either daily intravenous (IV) bolus injection or 24-hour continuous infusion. Administration of rh GM-CSF resulted in a broad spectrum of dose- and schedule-dependent hematopoietic effects. Sustained infusion of rh GM-CSF elicited a maximum 17-fold average peak increase of the total WBC count with mainly neutrophils, eosinophils, and monocytes accounting for this rise, and increases in bone marrow cellularity with a shift to immature myeloid elements. Elevation of lymphocytes, platelets, and reticulocytes was not induced. Within five days after discontinuation of treatment the leukocytosis had disappeared. Adverse reactions encountered with rh GM-CSF seen in 65% of the patients studied were never life-threatening and always rapidly reversible. They included mild myalgias, facial flushing, low-grade fever, headache, bone discomfort, nausea, dyspnea, and transient decline of platelet counts. These results suggest that rh GM-CSF can be safely administered at the doses and schedules used and that it can induce in vivo some of the biological effects reported in in vitro studies. Although no objective antitumour responses have been seen, the ability of rh GM-CSF to increase number and function of leukocytes in vivo may prevent neutropenia and infections when GM-CSF is added to cytotoxic cancer therapy. 相似文献
89.
Schreiber S Kämpgen E Wagner E Pirkhammer D Trcka J Korschan H Lindemann A Dorffner R Kittler H Kasteliz F Küpcü Z Sinski A Zatloukal K Buschle M Schmidt W Birnstiel M Kempe RE Voigt T Weber HA Pehamberger H Mertelsmann R Bröcker EB Wolff K Stingl G 《Human gene therapy》1999,10(6):983-993
We performed a phase I trial to evaluate the safety and tolerability of repeated skin injections of IL-2-transfected autologous melanoma cells into patients with advanced disease. Cell suspensions, propagated from excised metastases, were IL-2 gene transfected by adenovirus-enhanced transferrinfection and X-irradiated prior to injection. Vaccine production was successful in 54% of the patients. Fifteen patients (37%) received two to eight skin vaccinations of either 3 x 10(6) (intradermal) or 1 x 10(7) (half intradermal, half subcutaneous) transfected melanoma cells per vaccination (secreting 140-17,060 biological response modifier program units of IL-2/10(6) cells/24 hr). Analyses of safety and efficacy were carried out in 15 and 14 patients, respectively. Overall, the vaccine was well tolerated. All patients displayed modest local reactions (erythema, induration, and pruritus) and some experienced flu-like symptoms. Apart from newly appearing (4 of 14) and increasing (5 of 14) anti-adenovirus and newly detectable anti-nuclear antibody titers (1 of 15), recipients developed de novo or exhibited increased melanoma cell-specific delayed-type hypersensitivity (DTH) reactions (8 of 15) and vitiligo (3 of 15) and showed signs of tumor regression (3 of 15). This supports the idea of a vaccine-induced or -amplified anti-cancer immune response. None of the patients exhibited complete or partial regressions, but five of them experienced periods of disease stabilization. Three of these individuals received more than the four planned vaccinations and their mean survival time was 15.7 +/- 3.5 months as compared to 7.8 +/- 4.6 months for the entire patient cohort. These data indicate that IL-2-producing, autologous cancer cells can be safely administered to stage IV melanoma patients and could conceivably be of benefit to patients with less advanced disease. 相似文献
90.
Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells 总被引:6,自引:2,他引:6 下载免费PDF全文
E Platzer K Welte J L Gabrilove L Lu P Harris R Mertelsmann M A Moore 《The Journal of experimental medicine》1985,162(6):1788-1801
We studied the biological effects of pluripoietin, a human pluripotent hemopoietic colony-stimulating factor (CSF) purified from the 5637 bladder carcinoma cell line. We found that this human CSF appears to be a unique hemopoietic growth factor, differing from interleukin 3 (IL-3) by virtue of its leukemia differentiating activity in mouse and man, and from mouse granulocyte CSF, which does have differentiation-inducing activity, but lacks pluripoietic activity. In addition, differences from IL-3 were observed in cross-species activity on normal and leukemic cells. 相似文献